Skip to main content
Clinical Trials/NCT03799614
NCT03799614
Completed
N/A

Vibration Impact on Parkinson's Tremor

Virginia Commonwealth University1 site in 1 country30 target enrollmentFebruary 26, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Virginia Commonwealth University
Enrollment
30
Locations
1
Primary Endpoint
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The primary purpose of this study is to test the safety, tolerability and efficacy of vibration (delivered by an experimental device called RMBand that is worn on the subject's arm) on parkinsonian tremor. The RMBand was developed by Resonate Forward, LLC (RF). This RMBand is designed to administer a vibration to the wearer to decrease or stop tremor in persons with Parkinson's disease (PD).

Detailed Description

Participation will be completed in one visit at VCU Parkinson's and Movement Disorders Center. A baseline Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) will be taken prior to vibration therapy. The RMBand (experimental device) will be placed on the arm of the participant to provide the vibration therapy. The MDS-UPDRS Part III will be repeated both during and after the therapy. Participants will be asked to provide feedback about the device, the therapy session and how they are feeling.

Registry
clinicaltrials.gov
Start Date
February 26, 2019
End Date
November 27, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Parkinson's disease (PD) as diagnosed by a movement disorder specialist
  • Tremor caused by their Parkinson's disease
  • Ability to provide informed consent

Exclusion Criteria

  • Known diagnosis of Parkinson Plus Syndrome
  • Other known non-PD cause of tremor
  • Other known non-PD cause of limb dysfunction
  • Presence of implantable cardiac device, severe neuropathy or sensory loss that would prevent perception of vibration stimulus
  • Non-English speaker
  • Prisoners
  • Pregnant women

Outcomes

Primary Outcomes

Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)

Time Frame: This rating scale will be used at baseline, 5 minutes after vibration starts, and 5 minutes after vibration is turned off.

The "Movement Disorder Society Unified Parkinson Disease Rating Scale" (MDS-UPDRS) Part III, only, will be used at baseline, and repeated during vibration and post vibration data collection times. It is a validated scale administered by a clinician, contains 34 items to score between 0 (normal) and 4 (severe). The score range is 0 - 136. It takes \~ 5 minutes to complete. Lower scores are better. This outcome measure will be used to report a change in PD motor symptoms over time.

Clinical Rating for Tremor

Time Frame: Data collection times were baseline, 5 minutes after vibration start (vibration duration was 20 minutes), 5 minutes after vibration was stopped. .

Clinical Rating Scale for Tremor (Fahn, Tolosa, \& Marin) assesses severity of tremor symptoms. This scale takes 10-minutes, Items 1 - 14 will be used to report average changes in tremor. Items are rated on a scale of 0=normal to 4=severely abnormal, total summative score range for items 1- 14 points is 0 - 56. Lower scores are better. Total time to complete the Scale for Tremor assessment is 10 minutes.

Objective Measurement of Tremor Frequency (Hz)

Time Frame: Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.

This is a device that will objectively measure tremors frequency and amplitude pre, during, and post treatment.

Objective Measurement of Tremor Amplitude (mm).

Time Frame: Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.

This is a device that will objectively measure tremor amplitude pre, during, and post treatment.

Study Sites (1)

Loading locations...

Similar Trials